Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from PBMs. The companies are often building barriers to reimbursement, like steep cost requirements and PA that hinder user access. Industry believe that such reimburseme